Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318331 · ClinicalTrials.gov registry record · Phase 2
Enteral Glutamine in Critical Illness
A Phase 2 study, sponsored by Christiana Care Health Services.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00318331 is a Phase 2 study that was terminated before completion, run by Christiana Care Health Services. The registered enrollment target is 20 participants.
The verdict
NCT00318331, a Phase 2 study, was terminated before completion, sponsored by Christiana Care Health Services.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Glutamine is an amino acid which is rapidly depleted in critical illness. It is used as energy by cells that line the gut, vital for immune system function, and works as an anti-oxidant. Glutamine supplementation has been shown to improve outcomes in ICU patients. We hypothesize that critically ill patients given extra glutamine will have less of an inflammatory response and therefore better outcomes than patients not given extra glutamine. Our study randomizes patients to tube feeding with OR without extra glutamine to see if it affects patient outcomes as well as markers of inflammation.
Interventions
- DRUG Glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318331
The ClinicalTrials.gov registry entry for NCT00318331 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Christiana Care Health Services, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glutamine is the first listed.
NCT00318331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318331 about?
NCT00318331 is a clinical study titled "Enteral Glutamine in Critical Illness". Glutamine is an amino acid which is rapidly depleted in critical illness. It is used as energy by cells that line the gut, vital for immune system function, and works as an anti-oxidant. Glutamine supplementation has been shown to improve outcomes in ICU patients. We hypothesize that critically ill ...
What is the current status of trial NCT00318331?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-05. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00318331?
The interventions under investigation include: Glutamine (DRUG).
Who is sponsoring clinical trial NCT00318331?
This trial is sponsored by Christiana Care Health Services, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.